Wednesday, February 1, 2023
  • Login
The Science Serve
  • Home
  • Healthcare
  • Technology
  • Market
  • Contact Us
  • More
    • Privacy Policy
    • Disclaimer
    • Editorial Policy and Guidelines
    • Terms and Conditions
No Result
View All Result
The Science Serve
No Result
View All Result
Home Healthcare

Pros and cons of novel gene therapy for autism

Dr. Priyom Bose by Dr. Priyom Bose
November 24, 2020
in Healthcare
Reading Time: 3 mins read
0 0
A A
0
Pros and cons of novel gene therapy for autism
Share on FacebookShare on Twitter

Ultragenyx, California, and GeneTx, Florida, two biopharmaceutical companies, in collaboration with each other, started a small clinical trial to study the safety of gene therapy for Angelman syndrome. This trial is put on hold as two of the participants temporarily lost their ability to walk.

Angelman syndrome is a rare autism-related genetic condition that occurs due to mutation or absence of a gene named UBE3A, affecting normal neural developments. Typically, people inherit two copies of the UBE3A gene, where the maternal copy is active in neurons and the paternal copy is inactive or silent. In Angelman syndrome, the maternal copy is absent or mutated. As a result, the brain cells do not express active UBE3A protein. Such mutation causes balance and motor problems, intellectual disability, seizures, and sleep disorders. GTX-102, the drug administered in the trial, comprises a snippet RNA called an antisense oligonucleotide involved in the activation of the paternal copy of UBE3A protein. Researchers believed that such activation would restore the protein imbalance and thereby help patients with Angelman syndrome. Three other companies, namely, Biogen, Roche, and Ionis are conducting similar research to treat the syndrome.

Positive and Negative Effects of the Therapy

The clinical trial consisted of 5 participantswith Angelman syndrome aged between 5 and 15. Scientists had planned to inject a dose of GTX-102 to individual candidates once a month over four months. The drug would be injected directly into a specific site in the lower back. Over the months, the doses given to the participants would increase. Initially, each participant would start with a varying dose, for instance, two of the participants would receive the lowest dose, while the others would receive higher doses. The researchers evaluated positive results within the few days of the first administration of the drug to the participants. The participants showed improvements in sleep, communication, and motor skills.

https://www.needpix.com/photo/download/1016844/puzzle-dna-research-genetic-piece-3d-healthcare-health-science

Elizabeth Berry-Kravis, professor of child neurology at Rush University Medical Center in Chicago, Illinois, reported that two of the participants complained about losing the ability to walk, while the other three participants showed some weakness. These side effects occurred as a result of the inflamed nerves where the drug was injected. The researchers thought that such inflammation occurred maybe because of the drug accumulation in the injected area. However, the inflammation was reported to have reduced on administering appropriate anti-inflammatory drugs, and the participants could walk again. They were also found to be more coordinated than they were before the study.

Moving forward, Ultragenyx chief executive officer, Emil Kakkis, stated that that the company has planned to optimize the dose such that the participants would show the positive traits without developing any weakness in their legs. The researchers would also establish a new drug administration method such that no drug accumulation would occur. Scott Stromatt, chief medical officer of GeneTx, stated that they will seek approval from the U.S. Food and Drug Administration, and hope to resume their study within the next two months.

Post Views: 174
Dr. Priyom Bose

Dr. Priyom Bose

Dr. Priyom Bose is a plant researcher and experienced science writer. Dr. Priyom has completed her Ph.D. from the University of Madras. https://www.linkedin.com/in/priyom-bose-84b81b153/

POPULAR NEWS

  • Why are Men Taller than Women?

    Why are Men Taller than Women?

    0 shares
    Share 0 Tweet 0
  • DENTIST IN SPACE: UPCOMING ERA OF AEROSPACE DENTISTRY

    0 shares
    Share 0 Tweet 0
  • Development and Applications of electronic skin

    0 shares
    Share 0 Tweet 0
  • Discovery of World’s First Animal that Can Survive Without Oxygen

    0 shares
    Share 0 Tweet 0
  • Covid-19: Don’t DIY your immunity

    0 shares
    Share 0 Tweet 0
The Science Serve

We bring you the best Premium WordPress Themes that perfect for news, magazine, personal blog, etc.

Follow us on social media:

Recent News

  • Can memories be transferred?
  • Early life stress and Epigenetics of Depression
  • The first step towards genetic medicine for Transthyretin Amyloidosis

Category

  • Diagnosis
  • Featured
  • Health
  • Healthcare
  • Insights
  • Lifestyle
  • Market
  • Opinion
  • Science
  • Talk
  • Technology
  • Uncategorized

Recent News

Can memories be transferred?

Can memories be transferred?

December 13, 2022
Early life stress and Epigenetics of Depression

Early life stress and Epigenetics of Depression

October 21, 2022

© 2021 Thescienceserve

No Result
View All Result
  • Home
  • Healthcare
  • Technology
  • Market
  • Contact Us
  • More
    • Privacy Policy
    • Disclaimer
    • Editorial Policy and Guidelines
    • Terms and Conditions

© 2021 Thescienceserve

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?